BERENICE investigated the safety and efficacy of two neoadjuvant anthracycline-/taxane-containing regimens combined with dual HER2 blockade in cohorts of patients with early-stage, locally advanced, or inflammatory HER2+ breast cancer with normal cardiac function (n = 400). Here, ERBB2 is linked to breast cancer.